[Objective] To observe the clinical effect and safety of mifepristone treating EMT of peri-postmenstruation. [Method] Randomly divide 60 cases into control and observation groups, n=30; the control one takes Gestrinone; other mifepristone. Evaluate their clinical effects and side effects; test their serum CA-125 contents. [Result] The marked effective rate and total effective rate of observation group were much higher than those of control one, with difference of statistical meaning; the side effect rate was lower in observation one too with obvious difference; as well as the CA -125 content. [Conclusion] Mifepristone has definite cure effect on peri-postmenstruation period EMT, with little side effects, worthy clinical promotion.%[目的]探讨米非司酮治疗围绝经期子宫内膜异位症(EMT)的临床疗效以及安全性.[方法]将我院2010年1月到2011年5月收治的60例围绝经期EMT患者随机分为对照组与观察组,每组30例,对照组给予孕三烯酮治疗,观察组给予米非司酮治疗.评价临床疗效、两组不良反应发生情况,测定两组患者治疗前后的血清CA-125含量.[结果]观察组的显效率和总有效率均明显高于对照组,两组比较差异具有统计学意义(P＜0.05)；观察组不良反应发生率明显低于对照组,两组比较具有显著性差异(P＜0.05)；治疗后,观察组的CA-125含量明显低于对照组(P＜0.05).[结论]米非司酮临床治疗围绝经期EMT的疗效确切.
展开▼
